Medication Landscape
Oral and Emerging GLP-1 Medications (2026): Pills, Pipeline and What Is Real
Educational reference • Last reviewed August 5, 2026
Executive Summary
The biggest change in this category since the drugs launched was not a price cut — it was the pill. GLP-1 tablets for weight loss reached the U.S. market on January 5, 2026 and were being prescribed at scale within weeks. That removes the needle, the refrigerator, and the cold-chain shipping problem in one move, and it is already reshaping which providers can compete.
Behind the pill sits a pipeline that generates enormous search interest and almost no purchasable product. This guide separates the two: what you can actually get a prescription for today, what is filed and plausibly coming, and what is investigational — including one molecule being marketed to consumers that has no approved form at all.
Section 1: Available Now: Oral GLP-1s
Foundayo (orforglipron) — Eli Lilly
What it is: A once-daily oral GLP-1 tablet, FDA-approved for weight loss. Unlike oral semaglutide it is a small molecule, which is why it does not carry the same food and water timing restrictions.
Launched: January 5, 2026 in the United States. Within three weeks of launch it had been prescribed widely enough to register in national reporting.
Cost: Lilly publishes savings that can bring eligible patients to as little as $25 a month through LillyDirect. WeightWatchers has advertised a $25 first month.
Where to get it: LillyDirect, Walgreens, Hello Alpha, Dr. B, Calibrate, Ro, and WeightWatchers all list it.
Wegovy pill and Ozempic pill (oral semaglutide) — Novo Nordisk
What it is: Tablet formulations of semaglutide, the same molecule as the injectable pens.
Cost: NovoCare Pharmacy publishes both the Wegovy pill and the Ozempic pill from $149 per month — notably cheaper than the pen versions at $199 to $349.
Where to get it: NovoCare Pharmacy sells it directly with free home delivery, and any prescriber can write for it.
Rybelsus is the earlier oral semaglutide product approved for type 2 diabetes.
Compounded oral semaglutide and tirzepatide
What it is: Compounded tablets, troches, or drops offered by several telehealth platforms as a lower-cost oral option.
Regulatory status: Not FDA-approved. These are compounded preparations, not the approved oral products above.
Where you will see it: 24hrDoc at $179/month, PepScribe, Fitish RX, and Empower Pharmacy among others.
Note that Strive Pharmacy publicly declined to resume compounded oral semaglutide sales in 2026, which tells you something about how contested this category is.
Section 2: Filed or Coming: The Near Pipeline
| Medication | Maker | Status | Reported trial results |
|---|---|---|---|
| CagriSema | Novo Nordisk | FDA filing submitted early 2026; possible availability late 2026 or 2027 | Up to 22.7% weight loss in adults without diabetes; 15.7% in adults with type 2 diabetes |
| Survodutide | Boehringer Ingelheim | Phase III complete (SYNCHRONIZE-1); not yet approved | Average loss of up to 39.2 lb (17.8 kg) from baseline after 76 weeks |
| Elecoglipron | AstraZeneca | Phase 2b; early stage | 10.5% weight loss reported in phase 2b, alongside blood sugar reduction |
| Retatrutide | Eli Lilly | Investigational — NOT approved and not purchasable | Up to 28.3% weight loss reported in Phase 3 (TRIUMPH-1) |
Trial results are as reported by manufacturers and in published literature. None of these figures represent what an individual patient should expect, and none of these four medications can be legally dispensed as an approved product in the U.S. today.
Section 3: The Retatrutide Problem
If a provider offers you retatrutide, stop and think
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Its Phase 3 results — up to roughly 28% weight loss — are the best reported in the field, which is exactly why it generates so much consumer demand. It is also not FDA-approved, which means there is no approved product for any pharmacy to dispense.
- !It cannot legally be compounded. The FDA states directly that retatrutide and cagrilintide cannot be used in compounding under federal law. This is not a grey area or an interpretation — it is the agency's published position, and it makes any retatrutide offer a disqualifying signal about the provider making it.
- !You cannot verify what you are receiving. Without an approved reference standard, purity and potency claims are much harder to check than they already are for compounded semaglutide.
- !The safety profile is still being established. Phase 3 trials are how long-term safety gets characterised. That work is not finished.
- !Some sellers are not clinical operations at all. Retatrutide is widely sold in the “research chemical” grey market with no prescriber, no pharmacy, and no accountability.
A provider willing to sell you an unapproved molecule is telling you something about how it handles the approved ones. Our compounded provider assessment ranks on exactly this kind of disclosure.
Section 4: Oral vs Injectable: How to Choose
Reasons to prefer a pill
No needles, which matters more than clinicians often assume.
No refrigeration and no cold-chain shipping risk — see our storage and shipping guide for why that is a real problem.
No injection site reactions.
Easier to travel with.
Oral semaglutide through NovoCare is cheaper than the pen at $149 versus $199–$349.
Reasons to stay with an injection
The highest average weight loss figures still come from injectable tirzepatide.
Once weekly rather than once daily — fewer chances to forget.
Longer real-world track record, especially for tirzepatide.
Broader availability across compounded programs if cost is the binding constraint.
If you already tolerate an injectable well, switching has its own risks.
Our oral versus injectable GLP-1 article goes deeper on the clinical trade-offs, and switching between GLP-1 medications covers what changing actually involves.
Frequently Asked Questions
Is there a GLP-1 pill for weight loss?
Yes, as of 2026. Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1, launched in the United States on January 5, 2026 and had been widely prescribed within three weeks. Novo Nordisk separately sells Wegovy and Ozempic in tablet form through NovoCare Pharmacy. All of them require a prescription.
How much does Foundayo cost?
Eli Lilly publishes savings that can bring eligible patients to as little as $25 a month through LillyDirect, and WeightWatchers has advertised a $25 first month. Walgreens, Ro, and several telehealth platforms also prescribe it. Check the current published price before assuming — introductory pricing on new launches expires.
Is retatrutide available?
No. Retatrutide is Eli Lilly's investigational triple agonist and is not FDA-approved. Phase 3 data has shown up to roughly 28% weight loss, which is why it gets so much attention, but there is no approved product to dispense. Some telehealth platforms and compounding operations advertise it anyway — treat that as a serious red flag, not an opportunity.
When will CagriSema be available?
Novo Nordisk filed for FDA approval of CagriSema for weight loss in early 2026, and analysts have suggested availability as soon as late 2026 or early 2027 if approved. Trial data showed up to 22.7% weight loss in adults without diabetes and 15.7% in those with type 2 diabetes. Nothing is approved or purchasable yet.
Are oral GLP-1s as effective as injections?
Generally the oral options produce somewhat less weight loss than the strongest injectables, though the gap depends on which drugs you compare. What oral versions solve is adherence and logistics: no needles, no cold chain, no refrigeration, no injection-site reactions. For many people that trade-off is worth a few percentage points.